Sentences with phrase «relapse after transplant»
«Preventing graft - versus - host disease and relapse after transplant requires a difficult balance of eliminating the bad, overactive effector T cells, without suppressing the good, regulatory T cells,» said Kean, who is also an associate professor of pediatrics at the University of Washington School of Medicine and a member of the Fred Hutchinson Cancer Research Center.
https://www.sciencedaily.com/ Not exact matches
The findings, published online Nov. 13 in Science Translational Medicine, could pave the way for improvements in preventing GVHD and rejection of transplanted bone marrow and new therapies to prevent or treat a relapse of the underlying cancer after a transplant.
Targeting exhausted immune cells may change the prognosis for patients with acute myeloid leukemia (AML) relapse after a stem cell transplant, according to Penn State College of Medicine researchers.
As we are now able to focus our efforts on improving the overall patient experience and reducing the risk of relapse, the leading cause of death after transplant, we have greatly improved long - term survival outcomes for patients who before might not have had another treatment option.»
«The patients who participated in these trials had relapsed as many as four times, including 60 percent whose cancers came back even after stem cell transplants.
The therapy is approved by the U.S. Food and Drug Administration for relapsed or treatment - resistant Hodgkin lymphoma, and it is commonly prescribed to patients whose disease has progressed after autologous stem cell transplant, a procedure that replenishes the bone marrow with the patient's own healthy stem cells after therapy.
• Subject is refractory to or relapsed after first - line AML therapy (with or without hematopoietic stem cell transplant (HSCT)-RRB-.
A traditional goal of salvage therapy in the refractory / relapsed population has been to transition patients to transplant, but in trials of inotuzumab and blinatumomab, there has been no clear impact on survival after censoring patients at the time of transplant.
Brentuximab vedotin was previously approved by the FDA to treat cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after failure of other treatment, and primary cutaneous ALCL after failure of other treatment.
The US Food and Drug Administration (FDA) has granted Priority Review designation for tisagenlecleucel (Kymriah), formerly known as CTL019, for treatment of adult patients with relapsed or refractory diffuse large B - cell lymphoma (DLBCL) who are ineligible for, or have relapsed after, autologous stem cell transplant.